Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Non Operating Income (2017 - 2023)

Historic Non Operating Income for Denali Therapeutics (DNLI) over the last 7 years, with Q4 2023 value amounting to $13.1 million.

  • Denali Therapeutics' Non Operating Income rose 9713.21% to $13.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $51.5 million, marking a year-over-year increase of 24861.92%. This contributed to the annual value of $51.5 million for FY2023, which is 24861.92% up from last year.
  • Per Denali Therapeutics' latest filing, its Non Operating Income stood at $13.1 million for Q4 2023, which was up 9713.21% from $14.4 million recorded in Q3 2023.
  • In the past 5 years, Denali Therapeutics' Non Operating Income registered a high of $14.4 million during Q3 2023, and its lowest value of $1.0 million during Q3 2021.
  • Over the past 5 years, Denali Therapeutics' median Non Operating Income value was $3.3 million (recorded in 2019), while the average stood at $4.8 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 6158.36% in 2021, then skyrocketed by 76338.03% in 2023.
  • Quarter analysis of 5 years shows Denali Therapeutics' Non Operating Income stood at $3.8 million in 2019, then crashed by 57.2% to $1.6 million in 2020, then fell by 21.17% to $1.3 million in 2021, then surged by 418.29% to $6.7 million in 2022, then surged by 97.13% to $13.1 million in 2023.
  • Its Non Operating Income was $13.1 million in Q4 2023, compared to $14.4 million in Q3 2023 and $12.9 million in Q2 2023.